AF1q supports chronic myeloid leukemia cells survival by targeting CD44
Purpose: Tyrosine kinase inhibitors (TKIs) have emerged as the leading compound to treat chronic myeloid leukemia (CML) patients.Despite inspiring clinical results, resistance to TKIs and disease relapse remain a challenge for CML therapy.The human AFlq gene, known as a mix-lineage leukemia (MLL) gene”s fusion partner, is located on chromosome band1q21 and encodes a small protein of 9k Da.It was reported to be a poor prognostic biomarker for pediatric acute myeloid leukemia (AML), adult AML with normal cytogenetic and adult myelodysplastic syndrome and it may play a potential proto-oncogenic role in several solid tumors.In our previous study, we found that AFIq could regulate the expression of CD44 in 2 cell lines of breast carcinoma.The aim of this study was to elucidate the potential functions of AF 1 q in CML pathogenesis and drug resistance, identify that whether AFIq could regulate CD44 and further demonstrate the mechanisms of AFIq in CML.
Li Wei Ji Min Li Peng Lu Ting Yu Shuang Liu Yan Ma Daoxin Ji Chunyan
Department of Hematology, Qilu Hospital, Shandong University
国内会议
济南
英文
194-195
2015-06-05（万方平台首次上网日期，不代表论文的发表时间）